We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$33.5M
Cap. Flow %
-1.79%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.18%
2 Consumer Discretionary 5.28%
3 Financials 0.87%
4 Consumer Staples 0.28%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$55.2B
$152M 8.09%
400,000
-187,500
-32% -$60.4M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$132M 7.07%
71,178,364
– –
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$105M 5.62%
650,000
-15,000
-2% -$2.34M
WW
4
DELISTED
WW International
WW
$94.7M 5.06%
14,818,300
– –
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$92.9M 4.96%
525,000
-125,000
-19% -$18M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$38.3B
$87.5M 4.67%
600,000
-50,000
-8% -$7.09M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$73.8M 3.94%
1,100,000
-250,000
-19% -$15.9M
BLU
8
DELISTED
BELLUS Health Inc.
BLU
$64.7M 3.45%
7,000,000
-1,500,000
-18% -$12.3M
FATE icon
9
Fate Therapeutics
FATE
$275M
$64.4M 3.44%
2,600,000
+600,000
+30% +$16.6M
CYTK icon
10
Cytokinetics
CYTK
$10.6B
$50.1M 2.68%
1,275,000
+275,000
+28% +$11.1M
SRRK icon
11
Scholar Rock
SRRK
$5.88B
$48M 2.57%
8,750,034
+6,300,034
+257% +$45.3M
C icon
12
CALL
Citigroup
C
$213B
$46M 2.46%
+1,000,000
New +$50M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$43M 2.29%
4,000,000
– –
SEER icon
14
Seer Inc
SEER
$114M
$42.5M 2.27%
4,750,000
– –
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$39.7M 2.12%
1,500,000
– –
IGMS
16
DELISTED
IGM Biosciences
IGMS
$36.1M 1.93%
2,000,000
– –
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$35.8M 1.91%
1,650,000
– –
KRYS icon
18
Krystal Biotech
KRYS
$10.7B
$32.8M 1.75%
500,000
– –
LABU icon
19
CALL
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$517M
$27M 1.44%
+200,000
New +$34.1M
FHTX icon
20
Foghorn Therapeutics
FHTX
$278M
$23.4M 1.25%
1,720,720
– –
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
$22.2M 1.18%
900,000
+50,000
+6% +$1.83M
GOSS icon
22
Gossamer Bio
GOSS
$101M
$19.7M 1.05%
2,358,968
– –
KYMR icon
23
Kymera Therapeutics
KYMR
$8.66B
$19.7M 1.05%
1,000,000
– –
KURA icon
24
Kura Oncology
KURA
$793M
$19.2M 1.03%
1,050,000
– –
EQRX
25
DELISTED
EQRx, Inc. Common Stock
EQRX
$18.8M 1%
4,000,000
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group's Q2 2022 filing shows 7 new, 8 increased, 8 reduced and 9 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M. The largest sale was argenx, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.